BerandaGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
$10,72
Setelah Jam Perdagangan Normal:(0,00%)0,00
$10,72
Tutup: 15 Agu, 16.01.50 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$10,74
Rentang hari
$10,64 - $10,77
Rentang tahun
$6,19 - $11,14
Kapitalisasi pasar
9,02Â M USD
Volume Rata-Rata
1,32Â jt
Rasio P/E
21,05
Hasil dividen
1,64%
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(EUR) | Jun 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 1,89Â M | 4,03% |
Biaya operasional | 394,25Â jt | -5,69% |
Laba bersih | 117,06Â jt | 688,78% |
Margin laba bersih | 6,19 | 654,88% |
Penghasilan per saham | 0,22 | 58,44% |
EBITDA | 414,24Â jt | 13,12% |
Tarif pajak efektif | 27,36% | — |
Neraca
Total aset
Total liabilitas
(EUR) | Jun 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 582,38Â jt | -74,23% |
Total aset | 19,77Â M | -11,32% |
Total liabilitas | 12,17Â M | -13,05% |
Total ekuitas | 7,60 M | — |
Saham yang beredar | 679,77 jt | — |
Harga terhadap nilai buku | 1,41 | — |
Tingkat pengembalian aset | 4,29% | — |
Tingkat pengembalian modal | 4,91% | — |
Arus Kas
Perubahan kas bersih
(EUR) | Jun 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | 117,06Â jt | 688,78% |
Kas dari operasi | 155,27Â jt | -38,60% |
Kas dari investasi | -107,65Â jt | -107,98% |
Kas dari pembiayaan | -181,41Â jt | -405,19% |
Perubahan kas bersih | -194,12Â jt | -111,66% |
Arus kas bebas | 67,94Â jt | -95,81% |
Tentang
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Didirikan
18 Nov 1940
Situs
Karyawan
23.800